Foto del docente

Pier Giorgio Cojutti

Ricercatore a tempo determinato tipo b) (senior)

Dipartimento di Scienze Mediche e Chirurgiche

Settore scientifico disciplinare: BIO/14 FARMACOLOGIA

Pubblicazioni

Gatti M.; Virgili G.; Cojutti P.G.; Gaibani P.; Conti M.; Sturiale C.; Pea F.; Viale P., Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases, «MICROORGANISMS», 2022, 10, Article number: 154, pp. 1 - 8 [articolo]Open Access

Cojutti, Pier Giorgio; Rinaldi, Matteo; Zamparini, Eleonora; Rossi, Nicolò; Tedeschi, Sara; Conti, Matteo; Pea, Federico; Viale, Pierluigi, Reply to Baklouti et al., "Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?", «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2022, 66, Article number: e01908-21, pp. 1 - 1 [articolo]

Cojutti P.G.; Fornaro G.; Gatti M.; Rinaldi M.; Gaibani P.; Giannella M.; Pea F.; Viale P., Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring, «INFECTIOUS DISEASE REPORTS», 2022, 14, pp. 88 - 92 [articolo]Open Access

Gatti, Milo; Bartoletti, Michele; Cojutti, Pier Giorgio; Gaibani, Paolo; Conti, Matteo; Giannella, Maddalena; Viale, Pierluigi; Pea, Federico, A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol, «JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE», 2021, 27, pp. 294 - 298 [articolo]Open Access

Gatti M.; Cojutti P.G.; Campoli C.; Caramelli F.; Corvaglia L.T.; Lanari M.; Pession A.; Ramirez S.; Viale P.; Pea F., A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings, «FRONTIERS IN PHARMACOLOGY», 2021, 12, Article number: 755075, pp. 1 - 13 [articolo]Open Access

Gatti M.; Cojutti P.G.; Pascale R.; Tonetti T.; Laici C.; Dell'olio A.; Siniscalchi A.; Giannella M.; Viale P.; Pea F., Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections, «ANTIBIOTICS», 2021, 10, Article number: 1311, pp. 1 - 12 [articolo]Open Access

Cojutti P.G.; Londero A.; Della Siega P.; Givone F.; Fabris M.; Biasizzo J.; Tascini C.; Pea F., Authors’ Reply to Cattaneo et al.: “Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6”, «CLINICAL PHARMACOKINETICS», 2021, 60, pp. 833 - 834 [articolo]

Cojutti P.G.; Gatti M.; Rinaldi M.; Tonetti T.; Laici C.; Mega C.; Siniscalchi A.; Giannella M.; Viale P.; Pea F., Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization, «FRONTIERS IN PHARMACOLOGY», 2021, 12, Article number: 781892, pp. 1 - 11 [articolo]Open Access

Rinaldi, Matteo; Cojutti, Pier Giorgio; Zamparini, Eleonora; Tedeschi, Sara; Rossi, Nicolò; Conti, Matteo; Giannella, Maddalena; Pea, Federico; Viale, Pierluigi, Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2021, 65, Article number: 02038-20, pp. 1 - 33 [articolo]

Cojutti P.G.; Carnelutti A.; Lazzarotto D.; Sozio E.; Candoni A.; Fanin R.; Tascini C.; Pea F., Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: Should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles?, «PHARMACEUTICS», 2021, 13, Article number: 2099, pp. 1 - 13 [articolo]Open Access

Cojutti P.G.; Morandin E.; Baraldo M.; Pea F., Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2021, 58, Article number: 106408, pp. 1 - 9 [articolo]

Cojutti, Pier Giorgio; Rinaldi, Matteo; Zamparini, Eleonora; Rossi, Nicolò; Tedeschi, Sara; Conti, Matteo; Pea, Federico; Viale, Pierluigi, Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections, «ANTIMICROBIAL AGENTS AND CHEMOTHERAPY», 2021, 65, Article number: e02260-20, pp. 1 - 12 [articolo]

Cojutti, Pier Giorgio; Zanon, Ezio; Pasca, Samantha; Pea, Federico, Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency, «CLINICAL PHARMACOKINETICS», 2021, na, pp. 1 - 12 [articolo]

Cojutti P.G.; Rinaldi M.; Gatti M.; Tedeschi S.; Viale P.; Pea F., Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2021, 58, Article number: 106445, pp. 1 - 3 [articolo]

Cojutti P.G.; Londero A.; Della Siega P.; Givone F.; Fabris M.; Biasizzo J.; Tascini C.; Pea F., Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6, «CLINICAL PHARMACOKINETICS», 2020, 59, pp. 1251 - 1260 [articolo]Open Access

Ultimi avvisi

Al momento non sono presenti avvisi.